Skip to content

Repligen

US · RGEN #1445 by market cap Listed 1970
167.22 -7.64 -4.37%
Live - 5344 symbols - heartbeat 347s ago · 2026-10-08 05:35
Pre-market 165.14 -1.24%
After-hours 167.22 0.00%
Overnight 166.83 -0.23%
Market cap
10.62B
P/B
5.03
EPS
0.86
Reader sentiment Are you bullish or bearish on RGEN?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 5.06 Expensive vs history 70th percentile
5-year average 4.78 · #38 of 51 in Medical Instruments & Supplies
P/E ratio 259.40 Expensive vs history 87th percentile
5-year average 121.01 · forward 140.64 · #24 of 27 in Medical Instruments & Supplies
P/S ratio 13.61 Expensive vs history 70th percentile
5-year average 13.35 · forward 12.01 · #44 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Repligen (RGEN) 10.62B 229.07 5.03 0.00%
Intuitive Surgical (ISRG) 146.44B 47.54 8.06 0.00%
Becton Dickinson & Co (BDX) 49.07B 54.43 2.01 2.33%
ResMed (RMD) 31.78B 21.67 4.83 1.06%
Medline (MDLN) 31.10B 67.27 2.69 0.00%
Alcon (ALC) 30.45B 48.09 1.41 0.56%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value172.37 Economic moatNarrow UncertaintyHigh

Trading 3.1% below Morningstar's fair value estimate.

Fair value

Repligen Corp earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 10% premium over our quantitative fair value estimate of $172.37 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's valuation metrics undermine our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to EBITDA ratio of 63.6 lies in the top 10% globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be overvalued.

The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 1.1%, a core component of profitability, lies in the bottom 40% compared with global peers. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-10-08 05:35:55 · For reference only, not investment advice and not tailored to your situation.